- /
- Supported exchanges
- / US
- / TEVA.NYSE
Teva Pharma Industries Ltd ADR (TEVA NYSE) stock market data APIs
Teva Pharma Industries Ltd ADR Financial Data Overview
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Teva Pharma Industries Ltd ADR (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Teva Pharma Industries Ltd ADR data using free add-ons & libraries
Get Teva Pharma Industries Ltd ADR Fundamental Data
Teva Pharma Industries Ltd ADR Fundamental data includes:
- Net Revenue: 17 349 M
- EBITDA: 5 003 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Teva Pharma Industries Ltd ADR Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-04-29
- EPS/Forecast: 0.46
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Teva Pharma Industries Ltd ADR News
New
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Choosing between Novartis AG (NYSE:NVS) and Teva Pharmaceutical Industries (NYSE:TEVA) requires weighing the stability of an established innovator against the potential of a generic specialist undergo...
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
Supernus Pharmaceuticals (SUPN) shares rallied 5.2% in the last trading session to close at $50.44. This move can be attributable to notable volume with a higher number of shares being traded than in ...
Teva And Polpharma Biologics Ink Global Licensing Deal For Ocrevus Biosimilar
(RTTNews) - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA) and Polpharma Biologics International AG announced Thursday a global licensing agreement ...
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Teva secures exclusive global rights to commercialize Polpharma Biologics' biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.